Traditional Drug Pipeline Update: April 2023
Critical updates in an ever-changing environmentApril 27, 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.
See separate article for pipeline information on specialty drugs.
New Drug Information
- Rezzayo™ (rezafungin): The U.S. Food and Drug Administration (FDA) has approved Cidara and Melinta’s Rezzayo for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Rezzayo is an echinocandin antifungal that is supplied as a solid (cake or powder) in a single-dose vial containing 200mg of rezafungin. Treatment is administered once weekly by intravenous infusion after reconstitution. The approval was based on the Phase 3 ReSTORE study which demonstrated treatment with Rezzayo was found to be noninferior to caspofunginfor the primary endpoint of all-cause mortality at day 30, using a 20% noninferiority margin. All-cause mortality at day 30 was reported to be 23.7% for the Rezzayo group and 21.3% for the caspofungin group.1 Rezzayo launch and price are pending.
- Naloxone Hydrochloride Nasal Spray™ (naloxone): Amphastar’s Naloxone Hydrochloride Nasal Spray 4mg was approved by the FDA for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients. Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl.2Naloxone Hydrochloride Nasal Spray is supplied as a carton containing 2 unit-dose devices; each device delivers a single spray containing 4mg of naloxone hydrochloride (equivalent to 3.6mg of naloxone). The device is ready to use and does not require priming or testing prior to administration. According to IQVIA, the U.S. sales of previously approved naloxone hydrochloride nasal spray 4mg in 2022 was approximately $250 million for the 12 months ended December 31, 2022.3 Naloxone Hydrochloride Nasal Spray 4mg launch and price are pending.
- RizaFilm® (rizatriptan) oral film: The FDA has approved RizaFilm for the treatment of acute migraine. RizaFilm was approved via the 505(b)(2) pathway using Merck & Co.’s Maxalt® (rizatriptan benzoate) as its reference product. The global migraine drugs market was valued at nearly $3 billion in 2021 and is expected to reach nearly $11 billion by 2030, representing a compound annual growth rate of 15.6%.4 Launch and price are anticipated shortly.
Generic Drug Information
- Noxafil® Suspension (posaconazole susp 40 mg/mL): Multiple manufacturers launched their generic version of Merck Sharp & Dohme’s Noxafil suspension for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. Noxafil suspension is also indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole. Noxafil suspension generated $19 million in U.S. annual sales in 2022.
- Uceris® Rectal Foam (budesonide rectal foam, 2mg/act): Padagis has launched their version of Bausch Health’s Uceris rectal foam. Uceris rectal form is a glucocorticosteroid indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge. Uceris Rectal Foam generated $14 million in U.S. annual sales in 2022.
All New Indications for Specialty and Non-Specialty in 2023:
|Brand Name||Generic Name||Manufacture||Indication||Approval Date|
|Narcan® (nasal spray)||naloxone hydrochloride||Adapt Pharma/ Emergent BioSolutions/ Opiant||Opioid overdose||03/29/2023|
|Evkeeza® IV||evinacumab-dgnb||Regeneron||Certain forms of homozygous familial hypercholesterolemia (HoFH)||03/21/2023|
|Livmarli®||maralixibat chloride||Takeda/ Mirum Pharmaceuticals/ Shire||Alagille syndrome||03/13/2023|
|Revatio® (oral suspension)||sildenafil citrate||Pfizer/ Viatris||Pulmonary arterial hypertension||03/03/2023|
|Kevzara®||sarilumab||Sanofi/ Regeneron||Polymyalgia rheumatica||02/28/2023|
|Cibinqo® (tablet)||abrocitinib||Pfizer||Atopic dermatitis||02/09/2023|
|Eylea®||aflibercept||Regeneron||Retinopathy of prematurity (ROP)||02/08/2023|
|Trodelvy®||sacituzumab govitecan-hziy||Gilead/ Immunomedics||Certain forms of hormone receptor positive breast cancer||02/03/2023|
|Takhzyro® SC||lanadelumab||Takeda/ Dyax/ Shire||Prophylaxis against angioedema attacks in hereditary angioedema||02/03/2023|
|Tezspire®||tezepelumab-ekko||AstraZeneca/ Amgen/ MedImmune||Severe asthma||02/01/2023|
|Revatio® (tablet)||sildenafil citrate||Pfizer/ Viatris||Certain forms of pulmonary arterial hypertension||01/31/2023|
|Keytruda®||pembrolizumab||Merck & Co||Certain forms of Non-small cell lung cancer (NSCLC)||01/26/2023|
|Brukinsa®||zanubrutinib||BeiGene||Chronic lymphocytic leukemia||01/19/2023|
|Tukysa®||tucatinib||Seattle Genetics/ Seagen||Certain forms of colorectal cancer||01/19/2023|
June 8, 2023
July 2023 decisions expected from the FDA
At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…
June 8, 2023
HR to HX: Creating Moments that Matter
Prime Therapeutics’ (Prime) Senior Vice President and Chief Human Resources Officer (CHRO), Erin…
June 5, 2023
Oncology Update: Advances in Breast Cancer Management
New approvals and a broad pipeline promise advances in the treatment of breast…